TY - JOUR
T1 - Hormone response in ovarian cancer
T2 - Time to reconsider as a clinical target?
AU - Modugno, Francesmary
AU - Laskey, Robin
AU - Smith, Ashlee L.
AU - Andersen, Courtney L.
AU - Haluska, Paul
AU - Oesterreich, Steffi
PY - 2012/12
Y1 - 2012/12
N2 - Ovarian cancer is the sixth most common cancer worldwide among women in developed countries and the most lethal of all gynecologic malignancies. There is a critical need for the introduction of targeted therapies to improve outcome. Epidemiological evidence suggests a critical role for steroid hormones in ovarian tumorigenesis. There is also increasing evidence from in vitro studies that estrogen, progestin, and androgen regulate proliferation and invasion of epithelial ovarian cancer cells. Limited clinical trials have shown modest response rates; however, they have consistently identified a small subset of patients that respond very well to endocrine therapy with few side effects. We propose that it is timely to perform additional well-designed trials that should include biomarkers of response.
AB - Ovarian cancer is the sixth most common cancer worldwide among women in developed countries and the most lethal of all gynecologic malignancies. There is a critical need for the introduction of targeted therapies to improve outcome. Epidemiological evidence suggests a critical role for steroid hormones in ovarian tumorigenesis. There is also increasing evidence from in vitro studies that estrogen, progestin, and androgen regulate proliferation and invasion of epithelial ovarian cancer cells. Limited clinical trials have shown modest response rates; however, they have consistently identified a small subset of patients that respond very well to endocrine therapy with few side effects. We propose that it is timely to perform additional well-designed trials that should include biomarkers of response.
UR - http://www.scopus.com/inward/record.url?scp=84869225478&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869225478&partnerID=8YFLogxK
U2 - 10.1530/ERC-12-0175
DO - 10.1530/ERC-12-0175
M3 - Review article
C2 - 23045324
AN - SCOPUS:84869225478
SN - 1351-0088
VL - 19
SP - R255-R279
JO - Endocrine-Related Cancer
JF - Endocrine-Related Cancer
IS - 6
ER -